资讯

Eli Lilly (NYSE:LLY) Gains FDA Approval For New Alzheimer's Drug Dosing Schedule
Eli Lilly (NYSE:LLY) recently received FDA approval for a new dosing schedule of Kisunla, aimed at reducing amyloid-related ...
Fierce Pharma9 天
Eli Lilly's Kisunla wins FDA nod for new dosing with fewer side effects in Alzheimer's
The benefit-risk balance is tipping more in favor of Eli Lilly’s Kisunla in early Alzheimer’s disease as the FDA ...
BioSpace9 天
Lilly Gets FDA Label Update for Alzheimer’s Drug To Mitigate Safety Concerns
The FDA will allow a new dosing schedule for Eli Lilly’s Alzheimer’s drug Kisunla that could lessen a known side effect of ...
Stocktwits on MSN9 天
Eli Lilly’s Alzheimer’s Drug Gets US FDA Label Update For More Gradual Dosing After ...
Eli Lilly and Company (LLY) announced on Wednesday that the U.S. Food and Drug Administration (FDA) has approved a label ...
Pharmaceutical Technology29 天
Eli Lilly and Eisai’s Alzheimer’s drugs denied NHS use due to high costs
NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value for money”.
Eli Lilly (LLY) Secures FDA Label Update for Alzheimer’s Disease Treatment
Eli Lilly and Company (NYSE: LLY) is one of Goldman Sachs’ top healthcare stock picks. On July 9, the company confirmed the ...
BioSpace7 天
FDA Rejections: We Read 200 CRLs So You Don’t Have To
A journey through the FDA’s newly released complete response letters gave glimpses into the journeys to market for Eli ...
The Pharma Letter9 天
New dosing approved for Lilly’s Kisunla in Alzheimer’s
The US Food and Drug Administration (FDA) has approved a label update with a new recommended titration dosing schedule for ...
Precision Medicine Online7 天
Eli Lilly's Kisunla Gets New Dosing Schedule in FDA-Approved Labeling Update
The new dosing schedule with a more gradual titration significantly lowered incidence of ARIA-E in the TRAILBLAZER-ALZ 6 trial.
Eli Lilly and Company: FDA approves updated label for Lilly's Kisunla (donanemab-azbt) with ...
The newly recommended dosing schedule significantly lowered ARIA-E rates compared to the original dosing schedule, adding to the established safety profile of the treatment INDIANAPOLIS, ...
Medical Dialogues8 天
Eli Lilly gets USFDA okay for updated Kisunla label with new dosing in early symptomatic ...
Indianapolis: Eli Lilly and Company has received approval from the U.S. Food and Drug Administration (FDA) for a label update ...
pharmaphorum9 天
FDA clears new, safer regimen for Lilly's Alzheimer's drug
Eli Lilly has won a green light from the FDA for new dosing for its Alzheimer's disease therapy Kisunla, which carries a reduced risk of adverse reactions that may have held back its uptake in the ...